CLAIMS

1. A ~~solid~~ powdered pharmaceutical composition which is mixed with an aqueous solvent at the time of use, and is used as an adhesion preventing biomedical material, the composition comprising

(A) alginic acid or a pharmaceutically acceptable salt thereof which is not gelled~~a gelling agent~~,

(B) a salt having low water solubility consisting of a divalent metal and at least one selected from the group consisting of organic acids and inorganic acids, ~~and~~

(C) polyethylene glycol, and

(D) glucono-δ-lactone.

~~2. The pharmaceutical composition according to claim 1, further comprising (D) an organic acid or an alkali metal salt thereof.~~

~~3. The pharmaceutical composition according to claim 1 or 2, wherein the component (A) is alginic acid, a pharmaceutically acceptable alginic acid salt, or pectin.~~

~~4~~2. The pharmaceutical composition according to ~~any of claims~~ claim 1 ~~to 3~~, wherein the divalent metal in the component (B) is calcium.

~~5~~3. The pharmaceutical composition according to ~~any of claims~~ claim 1 ~~to~~ or 2~~4~~, wherein the component (B) is at least one

selected from the group consisting of dibasic calcium phosphate and calcium gluconate.

~~6~~4. The pharmaceutical composition according to any of claims 1 to ~~5~~3, wherein the component (C) has an average molecular weight of about 1000 to about 20000.

~~7~~5. The pharmaceutical composition according to ~~any of~~ claims 1 to ~~6~~4, wherein the component (C) is macrogol 4000.

~~8. The pharmaceutical composition according to any of claims 1 to 7, wherein the component (D) is gluconic acid or glucono-δ-lactone.~~

~~9~~6. The pharmaceutical composition according to ~~any of~~ claims 1 to ~~8~~5, comprising 3 to 50 parts by weight of the component (D) relative to 1 part by weight of the component (B).

~~10. The pharmaceutical composition according to any of claims 1 to 9, used as an adhesion preventing biomedical material.~~

~~11. The pharmaceutical composition according to any of claims 1 to 9, used as a hemostatic agent.~~

7. The pharmaceutical composition according to claims 1 to 6, wherein the component (C) content is 50 to 80 wt%.

~~12~~8. Use of a ~~solid~~ powdered pharmaceutical composition comprising (A) alginic acid or a pharmaceutically acceptable salt thereof which is not gelled~~a gelling agent~~, (B) a salt having low water solubility consisting of a divalent metal and at least one selected from the group consisting of organic acids and inorganic acids, ~~and~~ (C) polyethylene glycol, and (D) glucono-δ-lactone, for the manufacture of an adhesion preventing biomedical material which is mixed with an aqueous solvent at the time of use.

~~13. Use of a solid pharmaceutical composition containing (A) a gelling agent, (B) a salt of a divalent metal and at least one selected from the group consisting of organic acids and inorganic acids, and (C) polyethylene glycol, for the manufacture of a hemostatic agent.~~

~~14. An adhesion preventing method comprising the steps of:~~

~~preparing a solution by mixing an aqueous solvent with a solid pharmaceutical composition containing (A) a gelling agent, (B) a salt of a divalent metal and at least one selected from the group consisting of organic acids and inorganic acids, and (C) polyethylene glycol; and~~

~~administering the solution to an affected part where adhesion prevention is required.~~

~~15. A hemostatic method comprising the step of administering a solid pharmaceutical composition containing (A) a gelling~~

~~agent, (B) a salt of a divalent metal and at least one selected from the group consisting of organic acids and inorganic acids, and (C) polyethylene glycol to an affected part where hemostasis is required.~~